Molecular diagnostics system provider Nanosphere, Inc. (NSPH) announced that U.S. Food and Drug Administration has granted a de novo petition permitting marketing of its Gram-Positive Blood Culture Nucleic Acid Test or BC-GP on the automated sample-to-result Verigene System. The test will help fast detection of bacteria in bloodstream infections.
A single test using Verigene BC-GP would provide fast genus and species level detection for a broad panel of clinically significant gram-positive bacteria. The BC-GP test can detect markers such as mecA, vanA, and vanB genes, which confer resistance to the antibiotics methicillin/oxacillin and vancomycin.
William Moffitt, chief executive officer, said BC-GP test provides identification of bacteria and antimicrobial resistance genes from gram-positive blood culture bottles within two and a half hours, as compared with current microbiological methods, which can take up to two to three days.
Nanosphere said it plans to submit for FDA clearance in 2012.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.